Abingworth life science investment
Company news

Press room

 


Company News

Sanofi-aventis and Avila Therapeutics Sign Global Alliance to Develop Targeted Covalent Oncology Drugs
First covalent drug discovery partnership exploring multiple cancer targets
Waltham, MA, 20 December 2010
top
 
Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device
V-Go provides Type 2 diabetic patients a simple option for basal-bolus insulin therapy
Bridgewater, NJ, 08 December 2010
top
 
Syntaxin raises £18 million in new financing
To progress acromegaly programme and maximise potential of targeted secretion inhibitor platform
Oxford, UK, 11 November 2010
top
 
Dicerna Pharmaceuticals Announces Second Close of Series B Financing
SR One Joins as New Investor
Watertown, Mass, 21 October 2010
top
 
UCB and Synosia Therapeutics sign strategic alliance in neurology
Brussels & Basel, 12 October 2010
top
 
ABLYNX AND MERCK SERONO ENTER INTO SECOND AGREEMENT TO CO-DISCOVER AND CO-DEVELOP NANOBODIES®
Ghent, Belgium, 11 October 2010
top
 
Pathwork Diagnostics Completes $30M Series C Round
Capital to Accelerate Commercialization and Market Share for FDA-cleared Tissue of Origin Test
Redwood City, CA, 07 October 2010
top
 
IS Pharma plc
£3.6 million Cash Placing at 9% Premium and Maiden Dividend
Chester, UK, 06 October 2010
top
 
Dicerna Closes $25 Million Series B Financing
Proceeds Advance Next Generation RNAi-based Therapeutics Toward Clinical Development
Watertown, MA, 11 August 2010
top
 
Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capita
San Diego, CA, 13 July 2010
top
 
Infinity and Intellikine enter agreement to develop oral therapies targeting PI3 kinase delta, gamma
Cambridge, MA and La Jolla, CA, 08 July 2010
top
 
Abingworth makes Growth Equity Investment in Secure EDI
Commits up to $40m to support recapitalisation and growth
London, 05 May 2010
top
 
Abingworth wins Private Equity Award
London, 27 April 2010
top
 
Micromet Closes $80.5 Million Public Offering of Common Stock
Bethesa, Maryland, 17 March 2010
top
 
ABLYNX SUCCESSFULLY RAISES €50 MILLION WITH SECONDARY PUBLIC OFFERING
FINAL PRICE: €7.5 PER SHARE
Ghent, Belgium, 15 March 2010
top
 
Dicerna Signs Research Collaboration and License Agreement for Drug Delivery Systems and Dicer Substrate siRNA (DsiRNA) Pharmaceuticals with Kyowa Hakko Kirin
Watertown, Mass, 04 January 2010
top
 
Archive:
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.